Systemic anticancer therapy and overall survival in patients with very advanced solid tumors
Last Updated: Wednesday, June 26, 2024
This cohort study looked at 78,446 adult patients with 6 common metastatic solid tumors to determine if oncologic treatment of very advanced disease was associated with improved survival and found no statistically significant survival benefit for patients treated at practices that used more systemic therapy for very advanced cancer compared with patients treated at practices that used less.
Advertisement
News & Literature Highlights